CStone Pharmaceuticals of Suzhou announced US approval of its IND for CS1001, a novel PD-L1 candidate. CStone said the trial approval was the company’s first in the US. Developed using Ligand’s OMT transgenic animal platform, CS1001 is a fully human, full-length anti-PD-L1 monoclonal antibody, designed to mirror a natural G-type immune globulin 4 (IgG4) human antibody. Because of its design, CStone believes CS1001 will reduce the risk of immunogenicity and potential toxicities. The company started China trials of CS1001 one year ago.
Source: China Biotoday